Mesoblast (MESO) Common Equity (2015 - 2025)

Mesoblast (MESO) has reported Common Equity for 11 consecutive years, with $574.7 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity rose 24.59% year-over-year to $574.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $574.7 million (up 24.59% YoY) and the FY2025 annual result came in at $597.4 million, up 24.38% from the prior year.
• Common Equity declined to $574.7 million in Q4 2025 per MESO's latest filing, from $597.4 million in the prior quarter.
• Over the last five years, Common Equity for MESO reached as high as $600.9 million in Q1 2021 and fell as low as $461.3 million in Q4 2024.
• A 5-year average of $528.1 million and a median of $517.1 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity dropped 14.51% — and 2025, when it grew 24.59%.
• Year by year, Common Equity stood at $535.5 million in 2021, then declined by 6.63% to $500.0 million in 2022, then gained by 1.75% to $508.7 million in 2023, then slipped by 9.33% to $461.3 million in 2024, then climbed by 24.59% to $574.7 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $574.7 million, $597.4 million, and $461.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.